LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-Implications for LDL management

Journal of Clinical Lipidology

Volumn 1, Issue 6, 2007, Pages 583-592

  Cromwell, William C ^a,b   Otvos, James D ^c   Keyes, Michelle J ^d,e   Pencina, Michael J ^e   Sullivan, Lisa ^f   Vasan, Ramachandran S ^d   Wilson, Peter W F ^g   D'Agostino, Ralph B ^d,e  

^a Presbyterian Center for Preventive Cardiology   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c LIPOSCIENCE INC   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Boston University   (United States)

^f BOSTON UNIVERSITY   (United States)

^g EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; LDL cholesterol; LDL particle number; Non HDL cholesterol; Nuclear magnetic resonance

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; INSULIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 36749101948     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.10.001     Document Type: Article

References (39)

1. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
2. Sniderman A., Vu H., and Cianflone K. Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apoB levels. Atherosclerosis 89 (1991) 109-116
3. Jeyarajah E.J., Cromwell W.C., and Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006) 847-870
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
5. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
6. Otvos J.D., Jeyarajah E.J., and Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90 suppl (2002) 22i-29i
7. Cromwell W.C., and Otvos J.D. Low-density lipoprotein particle number and risk for cardiovascular disease. Curr Atheroscler Rep 6 (2004) 381-387
8. Sniderman A.D., Furberg C.D., Keech A., et al. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin therapy treatment. Lancet 361 (2003) 777-780
9. Sniderman A.D., St-Pierre A.C., Cantin B., Dagenais G.R., Despres J.-P., and Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 91 (2003) 1173-1177
10. Kim B.J., Hwang S.T., Sung K.C., et al. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem 51 (2005) 2257-2263
11. Stein E.A., Sniderman A., and Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 96 suppl (2005) 36K-43K
12. Kathiresan S., Otvos J.D., Sullivan L.M., et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation 113 (2006) 20-29
13. Cromwell W.C., and Otvos J.D. Heterogeneity of low density lipoprotein particle number in patients with type 2 diabetes mellitus and low density lipoprotein cholesterol <100 mg/dl. Am J Cardiol 98 (2006) 1599-1602
14. Ingelsson E., Schaefer E.J., Contois J.H., et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 298 (2007) 776-785
15. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 106 (2002) 2526-2529
16. Liu J., Sempos C.T., Donahue R.P., Dorn J., Trevisan M., and Grundy S.M. Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol 98 (2006) 1363-1368
17. Kannel W.B., Feinleib M., McNamara P.M., Garrison R.J., and Castelli W.P. An investigation of coronary heart disease in families. The Framingham offspring study. Am J Epidemiol 110 (1979) 281-290
18. McNamara J.R., and Schaefer E.J. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 166 (1987) 1-8
19. Freedman D.S., Otvos J.D., Jeyarajah E.J., et al. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: The Framingham Study. Clin Chem 50 (2004) 1189-1200
20. McNamara J.R., Small D.M., Li Z., and Schaefer E.J. Differences in LDL subspecies involve alterations in lipid composition and conformational changes in apolipoprotein B. J Lipid Res 37 (1996) 1924-1935
21. Some risk factors related to the annual incidence of cardiovascular disease and death in pooled repeated biennial measurements. Framingham Heart Study: 30 Year Follow-Up (1987), US Department of Health and Human Services, Bethesda, MD
22. Harvengt C., Heller F.R., Martiat P., and Van Nieuwenhuyze Y. Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects. J Clin Pharmacol 27 (1987) 475-480
23. Festa A., Williams K., Hanley A.J.G., et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 111 (2005) 3465-3472
24. Kuller L.H., Arnold A., Tracy R., et al. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 22 (2002) 1175-1180
25. Rosenson R.S., Otvos J.D., and Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) Trial. Am J Cardiol 90 (2002) 89-94
26. Blake G.J., Otvos J.D., Rifai N., and Ridker P.M. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation 106 (2002) 1930-1937
27. Otvos J.D., Collins D., Freedman D.S., et al. LDL and HDL particle subclasses predict coronary events and are changed favorably by gemfibrozil therapy in the Veterans Affairs HDL Intervention Trial (VA-HIT). Circulation 113 (2006) 1556-1563
28. Hayward R.A., Hofer T.P., and Sandeep V. Lack of evidence for recommended low-density lipoprotein treatment targets: a solvable problem. Ann Intern Med 145 (2006) 520-530
29. Davidson M.H. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 96 suppl (2005) 3K-13K
30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
31. Deedwania P., Barter P., Carmena R., et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
32. Berneis K.K., and Krauss R.M. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 43 (2002) 1363-1379
33. Barter P.J., Brewer Jr. H.B., Chapman M.J., Hennekens C.H., Rader D.J., and Tall A.R. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 23 (2003) 160-167
34. Guerin M., Lassel T.S., Le Goff W., Farnier M.A., and Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesterol ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
35. Miller M., Dolinar C., Cromwell W., and Otvos J.D. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol 87 (2001) 232-234
36. Rosenson R.S., Shalaurova I., Freedman D.S., and Otvos J.D. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I Trial. Atherosclerosis 160 (2002) 41-48
37. Blake G.J., Albert M.A., Rifai N., and Ridker P.M. Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial. Eur Heart J 24 (2003) 1843-1847
38. Soedamah S.S., Colhoun H.M., Thomason M.J., et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischemic heart disease. Atherosclerosis 167 (2003) 243-255
39. Barter P.J., Ballantyne C.M., Carmena R., et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258